Stock VERV VERVE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Verve Therapeutics, Inc.

Equities

VERV

US92539P1012

Real-time Estimate Cboe BZX
Other stock markets
 12:49:44 2024-05-23 pm EDT 		5-day change 1st Jan Change
5.355 USD -4.37% Intraday chart for Verve Therapeutics, Inc. -15.67% -61.41%
May. 16 Verve Therapeutics CFO Andrew Ashe Executes Purchase of 76,000 Shares of Common Stock; Shares Jump Premarket MT
May. 08 Verve Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Verve Therapeutics : Proof of concept for in vivo Base Editing to Inactivate the PCSK9 Gene and Lower LDL Cholesterol in Humans
PU
Verve Therapeutics : Characterization of Guide RNA Site Consistency Across Ancestries and the Potential for Off Target Editing with the Clinical Stage Base Editing Medicine, VERVE 101
PU
Verve Therapeutics CFO Andrew Ashe Executes Purchase of 76,000 Shares of Common Stock; Shares Jump Premarket
MT
Verve Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Verve Therapeutics: Q1 Earnings Snapshot
AQ
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
GL
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
GL
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
CI
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities laws
PR
Stifel Cuts Price Target on Verve Therapeutics to $40 From $56, Maintains Buy Rating
MT
Sector Update: Health Care Stocks Slide Late Afternoon
MT
Top Midday Decliners
MT
Looming Factory Orders, Job Openings Data Prompt Lower Premarket Action for US Equity Futures
MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday
MT
Sector Update: Health Care
MT
Verve Therapeutics Pauses Heart-1 Trial After Serious Adverse Events; Shares Fall Pre-Bell
MT
Top Premarket Decliners
MT
Verve Therapeutics Announces Updates on its PCSK9 Program
GL
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VERV Stock
  4. News Verve Therapeutics, Inc.